# US 2020/0390830 A1 · Systems and methods for treating a dysbiosis using fecal-derived bacterial populations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390830 A1
- Document ID: US20200390830A1
- Status: Published application
- Kind: A1
- Application number: 15/754,765
- Filed: 2016-08-24
- Published: 2020-12-17
- Earliest claimed: 2015-08-24
- Applicants: NuByiota LLC
- Inventors: Emma Allen-Vercoe
- Web page: https://patentgrep.com/patent/US20200390830A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 31/04: Antibacterial agents
- A61P 39/02: Antidotes
- C12N 1/20: Bacteria; Culture media therefor
- C12Q 1/10: Enterobacteria
- G01N 2333/33: from Clostridium (G)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides a method, wherein the method treats a subject having a dysbiosis, the method comprising: determining a first metabolic profile of the gut microbiome of a subject having a dysbiosis; changing the first metabolic profile of the gut microbiome of the subject to a second metabolic profile of the gut microbiome of the subject, by administering to the subject a composition comprising at least one bacterial species selected from the group consisting of: Acidaminococcus intestinalis, Bacteriodes ovatus, Bifidobacterium adolescentis, Bifidobacterium longum, Blautia sp., Clostridium sp., Collinsella aerofaciens, Escherichia coli, Eubacterium desmolans, Eubacterium eligens, Eubacterium limosum, Faecallbacterum prausnitzii, Lachnospira pectinoshiza, Lactobacillus casei, Parabacteroides distasonis, Roseburia faecalis, Roseburia intestinalis, Ruminococcus sp., Ruminococcus species, and Ruminococcus torques, wherein the composition is administered at a therapeutically effective amount, sufficient to alter the first metabolic profile of the gut microbiome to the second metabolic profile of the gut microbiome.

## Claims

### Claim 1

A method, wherein the method treats a subject having a dysbiosis, the method comprising:
a. determining a first metabolic profile of the gut microbiome of a subject having a dysbiosis; and
b. changing the first metabolic profile of the gut microbiome of the subject to a second metabolic profile of the gut microbiome of the subject, by administering to the subject a composition comprising at least one bacterial strain selected from the group consisting of Acidaminococcus intestinalis 14LG, Bacteroides ovatus 5MM, Bifidobacterium adolescentis 20MRS, Bifidobacterium longum, Blautia sp. 27FM Clostridium sp. 21FAA, Collinsella aerofaciens, Escherichia coli 3FM4i, Eubacterium desmolans 48FAA, Eubacterium eligens FFAA, Eubacterium limosum 13LG, Faecalibacterum prausnitzii 40FAA, Lachnospira pectinoshiza 34FAA, Lactobacillus casei 25MRS, Parabacteroides distasonis 5FM, Roseburia faecalis 39FAA, Roseburia intestinalis 31FAA, Ruminococcus sp. 11FM, Ruminococcus species, and Ruminococcus torques 30FAA,
wherein the composition is administered at a therapeutically effective amount, sufficient to alter the first metabolic profile of the gut microbiome to the second metabolic profile of the gut microbiome,
wherein the first metabolic profile of the gut microbiome is a consequence of the dysbiosis, wherein the second metabolic profile of the gut microbiome treats the subject having the dysbiosis.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition is administered at therapeutically effective amount, sufficient to colonize the gut of the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition comprises at least one bacterial strain selected from the group consisting of: 16-6-I 21 FAA 92% Clostridium cocleatum: 16-6-I 2 MRS 95% Blautia luti; 16-6-I 34 FAA 95% Lachnospira pectinoschiza; 32-6-I30 D6 FAA 96% Clostridium glycyrrhizinilyticum; and 32-6-I 28 D6 FAA 94% Clostridium lactatifermentans.

### Claim 4 (depends on 1)

The method of claim 1, wherein the dysbiosis is associated with gastrointestinal inflammation.

### Claim 5 (depends on 4)

The method of claim 4, wherein the gastrointestinal inflammation is a result of at least one disease selected from the group consisting of: inflammatory bowel disease, irritable bowel syndrome, diverticular disease, ulcerative colitis, Crohn's disease, and indeterminate colitis.

### Claim 6 (depends on 1)

The method of claim 1, wherein the dysbiosis is a Clostridium difficile infection.

### Claim 7 (depends on 1)

The method of claim 1, wherein the dysbiosis is food poisoning.

### Claim 8 (depends on 1)

The method of claim 1, wherein the dysbiosis chemotherapy-related dysbiosis.

### Claim 9

A method, wherein the method treats a subject having a dysbiosis, the method comprising:
a. determining a first metabolic profile of the gut microbiome of a subject having a dysbiosis; and
b. changing the first metabolic profile of the gut microbiome of the subject to a second metabolic profile of the gut microbiome of the subject, by administering to the subject a composition comprising at least one bacterial species selected from the group consisting of Acidaminococcus intestinalis, Bacteroides ovatus, Bifidobacterium adolescentis, Bifidobacterium longum, Blautia sp., Clostridium sp., Collinsella aerofaciens, Escherichia coli, Eubacterium desmolans, Eubacterium eligens, Eubacterium limosum, Faecalibacterum prausnitzii, Lachnospira pectinoshiza, Lactobacillus casei, Parabacteroides distasonis, Roseburia faecalis, Roseburia intestinalis, Ruminococcus sp., Ruminococcus species, and Ruminococcus torques,
wherein the composition is administered at a therapeutically effective amount, sufficient to alter the first metabolic profile of the gut microbiome to the second metabolic profile of the gut microbiome,
wherein the first metabolic profile of the gut microbiome is a consequence of the dysbiosis, wherein the second metabolic profile of the gut microbiome treats the subject having the dysbiosis.

### Claim 10 (depends on 9)

The method of claim 9, wherein the composition is administered at therapeutically effective amount, sufficient to colonize the gut of the subject.

### Claim 11 (depends on 9)

The method of claim 9, wherein the composition comprises at least one bacterial species selected from the group consisting of: Clostridium cocleatum: Blautia luti; Lachnospira pectinoschiza; Clostridium glycyrrhizinilyticum; and Clostridium lactatifermentans.

### Claim 12 (depends on 9)

The method of claim 9, wherein the dysbiosis is associated with gastrointestinal inflammation.

### Claim 13 (depends on 12)

The method of claim 12, wherein the gastrointestinal inflammation is a result of at least one disease selected from the group consisting of: inflammatory bowel disease, irritable bowel syndrome, diverticular disease, ulcerative colitis, Crohn's disease, and indeterminate colitis.

### Claim 14 (depends on 9)

The method of claim 9, wherein the dysbiosis is a Clostridium difficile infection.

### Claim 15 (depends on 9)

The method of claim 9, wherein the dysbiosis is food poisoning.

### Claim 16 (depends on 9)

The method of claim 9, wherein the dysbiosis chemotherapy-related dysbiosis.
